Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 12, 2026 18:09 ET | Source: Sanofi Winthrop Industrie

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

FDA approves Sanofi's Tzield as first disease-modifying therapy for children 8-17 with stage 3 type 1 diabetes, delaying insulin decline based on PROTECT
June 12, 2026 18:09 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse : Le Tzield de Sanofi approuvé aux États-Unis comme première thérapie modificatrice de la maladie pour les patients récemment diagnostiqués avec un diabète de type 1 au stade 3

La FDA approuve le Tzield de Sanofi comme première thérapie modificatrice pour enfants 8-17 ans atteints de diabète type 1 stade 3, retardant le déclin ins
March 08, 2023 17:36 ET | Source: MacroGenics, Inc.

MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million

ROCKVILLE, MD, March 08, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...